HIV Drugs Market Rising in United States | Fortune Business Insights

 The global HIV drugs market is set to gain traction from the increasing development of antiretroviral therapy to make it a first long-acting injectable formulation and a long-acting suppression (ATLAS). Physicians often anticipate that the ATLAS regimen can efficiently improve the compliance rates and can be made available in the once-a-month dosage form. In January 2021, for instance, Evergreen Health bagged the U.S. FDA approval for Cabenuva. It is the first complete and injectable regimen for HIV-1 infected adults that can be registered once every month. As per a published report by Fortune Business Insights™, titled, “HIV Drugs Market, 2021-2028,” the market stood at USD 28.79 billion in 2020. It is projected to grow from USD 30.46 billion in 2021 to USD 45.58 billion in 2028 at a CAGR of 5.9% in the forecast period.

Get Sample PDF Brochure:  https://www.fortunebusinessinsights.com/enquiry/sample/hiv-aids-drugs-market-101115

Merck Receives Approval from U.S. FDA for PIFELTRO and DELSTRIGO

In September 2019, Merck announced that it received the U.S. FDA approval for DELSTRIGO™ (as a complete regimen) and PIFELTRO™ (in combination with other antiretroviral agents). These will be used in adult patients for the treatment of HIV-1 infection. These patients will have to be suppressed on a stable antiretroviral regimen with no history of substitutions related to the resistance to both drugs and treatment failures. As per one of the company officials, “These broadened indications would help certain people with HIV-1 infection to move towards PIFELTRO and DELSTRIGO from their current antiretroviral therapy by combining other antiretroviral agents.” Such initiatives by reputed players would bolster the demand for these drugs in the near future.

Increasing Cases of HIV Infections to Boost Demand for HIV Drugs Worldwide

In developing regions, such as Africa, the cases of HIV infections are surging rapidly. It is set to drive the HIV drugs market growth. The World Health Organization (WHO) mentioned that in 2019, 1.7 million new HIV-infected patients were reported, while 33.0 million people were living with the infection globally. Besides, the Joint United Nations Programme on HIV/AIDS (UNAIDS) stated that in 2019, there were approximately 5.8 million HIV-infected individuals in Asia Pacific, 20.7 million people in Eastern and Southern Africa, and 2.2 million people in Western & Central Europe and North America. However, the ongoing COVID-19 pandemic has resulted in the reduced demand for antiretroviral drugs, which, in turn, may hamper growth.

COVID-19 Pandemic: Declining Number of New Patient Prescriptions to Hamper Growth

The COVID-19 pandemic has severely affected the import and export activities of healthcare products worldwide on account of nationwide lockdowns and disturbances in supply chains. Besides, the reduced number of new patient prescriptions in highly COVID-impacted areas has further lowered the demand for antibiotic and antiretroviral HIV drugs. We are providing elaborate reports to help you find the best solution to enhance your businesses amid the pandemic.

Speak To Our Analyst: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/hiv-aids-drugs-market-101115

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com


Comments

Popular posts from this blog

Pulse Oximeters Market Rising in United States | Fortune Business Insights

Behandlung von idiopathischer entzündlicher Myopathie Marktgröße, Anteil, Wachstum, Berichtsanalyse 2023

Eyewear Market In United States | Fortune Business Insights